ATE391504T1 - Neue imidazolidinderivate, deren herstellung und verwendung als vla4-antagonisten - Google Patents

Neue imidazolidinderivate, deren herstellung und verwendung als vla4-antagonisten

Info

Publication number: ATE391504T1
Authority: AT; Austria
Prior art keywords: preparation; imidazolidine derivatives; vla4 antagonists; new imidazolidine; new
Prior art date: 2001-08-01

Application number

AT02764740T

Other languages

English (en)

Inventor

Volkmar Wehner

Stefanie Flohr

Horst Blum

Hartmut Ruetten

Hans Ulrich Stilz

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-01

Filing date

2002-07-20

Publication date

2008-04-15

2002-07-20 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE391504T1 publication Critical patent/ATE391504T1/de

Links

239000005557 antagonist Substances 0.000 title 1
150000002461 imidazolidines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02764740T 2001-08-01 2002-07-20 Neue imidazolidinderivate, deren herstellung und verwendung als vla4-antagonisten ATE391504T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10137595A DE10137595A1 (de)	2001-08-01	2001-08-01	Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung

Publications (1)

Publication Number	Publication Date
ATE391504T1 true ATE391504T1 (de)	2008-04-15

Family

ID=7693930

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02764740T ATE391504T1 (de)	2001-08-01	2002-07-20	Neue imidazolidinderivate, deren herstellung und verwendung als vla4-antagonisten

Country Status (29)

Country	Link
US (1)	US6962937B2 (de)
EP (1)	EP1414444B1 (de)
JP (1)	JP4676697B2 (de)
KR (1)	KR100910930B1 (de)
CN (1)	CN1537000B (de)
AR (1)	AR036349A1 (de)
AT (1)	ATE391504T1 (de)
AU (1)	AU2002328931B2 (de)
BR (1)	BR0211535A (de)
CA (1)	CA2455966C (de)
CO (1)	CO5550452A2 (de)
DE (2)	DE10137595A1 (de)
DK (1)	DK1414444T3 (de)
ES (1)	ES2301673T3 (de)
HR (1)	HRP20040108A2 (de)
HU (1)	HUP0401406A3 (de)
IL (2)	IL160093A0 (de)
MX (1)	MXPA04000041A (de)
MY (1)	MY133467A (de)
NO (1)	NO326696B1 (de)
NZ (1)	NZ530887A (de)
PE (1)	PE20030348A1 (de)
PL (1)	PL365396A1 (de)
PT (1)	PT1414444E (de)
RS (1)	RS6104A (de)
RU (1)	RU2318815C2 (de)
TW (1)	TWI325863B (de)
WO (1)	WO2003011288A1 (de)
ZA (1)	ZA200400194B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4617449B2 (ja)	2002-07-11	2011-01-26	ヴィキュロンファーマシューティカルズインコーポレイテッド	抗菌活性を有するｎ−ヒドロキシアミド誘導体
EP2093218A1 (de) *	2008-02-22	2009-08-26	Ruggero Fariello	Arylalkylsubstituierte Imidazolidinone
MX2010012080A (es) *	2008-05-05	2011-04-11	Univ Winthrop Hospital	Metodo para mejorar el perfil de riesgo cardiovascular de los inhibidores de cox.
ES2997080T3 (en)	2010-10-25	2025-02-14	Biogen Ma Inc	Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
US12296054B2 (en)	2020-06-01	2025-05-13	Lg Chem, Ltd.	Method of preparing polymeric microparticles, polymeric microparticles, medical composition, cosmetic composition, medical articles and cosmetic articles using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE235866C (de)
DE4009506A1 (de) *	1990-03-24	1991-09-26	Hoechst Ag	Hydantoinderivate
DE4126277A1 (de) *	1991-08-08	1993-02-11	Cassella Ag	Hydantoinderivate
WO1993013798A1 (en)	1992-01-13	1993-07-22	Biogen, Inc.	Treatment for asthma
ES2103468T3 (es)	1992-02-12	1997-09-16	Biogen Inc	Tratamiento de la inflamacion intestinal.
DE4207254A1 (de)	1992-03-07	1993-09-09	Cassella Ag	4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) *	1992-04-24	1993-10-28	Cassella Ag	2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) *	1992-07-24	1994-01-27	Cassella Ag	Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) *	1992-08-28	1994-03-03	Cassella Ag	Imidazolidin-Derivate
WO1994015958A2 (en)	1993-01-08	1994-07-21	Tanabe Seiyaku Co., Ltd.	Peptide inhibitors of cell adhesion
CA2153692C (en)	1993-01-12	2011-11-08	Roy R. Lobb	Recombinant anti-vla4 antibody molecules
ES2114183T5 (es)	1993-02-09	2006-06-16	Biogen Idec Ma, Inc.	Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
DE4308034A1 (de) *	1993-03-13	1994-09-15	Cassella Ag	Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de)	1993-11-15	1996-02-15	Cassella Ag	Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en)	1993-12-06	1998-06-25	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
AU703152B2 (en)	1994-01-25	1999-03-18	Biogen Ma Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
AU2958195A (en)	1994-06-29	1996-01-25	Texas Biotechnology Corporation	Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en)	1994-08-25	1998-09-22	Cytel Corporation	Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en)	1994-12-24	1996-01-31	Zeneca Ltd	Chemical compounds
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
DE19515177A1 (de)	1995-04-28	1996-10-31	Cassella Ag	Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
DE59706273D1 (de) *	1996-03-20	2002-03-21	Hoechst Ag	Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
SG124234A1 (en)	1996-07-25	2006-08-30	Biogen Idec Inc	Cell adhesion inhibitors
DE19647382A1 (de) *	1996-11-15	1998-05-20	Hoechst Ag	Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) *	1996-11-15	1998-05-20	Hoechst Ag	Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de)	1996-11-15	1998-05-20	Hoechst Ag	5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
WO1998042656A1 (en)	1997-03-21	1998-10-01	Cytel Corporation	Novel compounds
DE19741235A1 (de) *	1997-09-18	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) *	1997-09-23	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE69835688T2 (de)	1997-10-31	2007-10-04	Aventis Pharma Ltd., West Malling	Substituierte anilide
GB9723789D0 (en)	1997-11-12	1998-01-07	Zeneca Ltd	Chemical compounds
DE19751251A1 (de) *	1997-11-19	1999-05-20	Hoechst Marion Roussel De Gmbh	Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999054321A1 (en)	1998-04-21	1999-10-28	Aventis Pharma Limited	Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de)	1998-05-14	1999-11-18	Hoechst Marion Roussel De Gmbh	Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ20004909A3 (cs)	1998-06-30	2002-04-17	Pfizer Products Inc.	Nepeptidové inhibitory VLA-4 dependentní buněčné vazby pouľitelné při léčení zánětlivých, autoimunitních a respiračních chorob
AU1915399A (en)	1998-07-10	2000-02-01	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
DE19922462A1 (de) *	1999-05-17	2000-11-23	Aventis Pharma Gmbh	Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate

2001
- 2001-08-01 DE DE10137595A patent/DE10137595A1/de not_active Withdrawn
2002
- 2002-07-20 IL IL16009302A patent/IL160093A0/xx unknown
- 2002-07-20 EP EP02764740A patent/EP1414444B1/de not_active Expired - Lifetime
- 2002-07-20 PL PL02365396A patent/PL365396A1/xx not_active Application Discontinuation
- 2002-07-20 BR BR0211535-2A patent/BR0211535A/pt active Search and Examination
- 2002-07-20 CA CA2455966A patent/CA2455966C/en not_active Expired - Fee Related
- 2002-07-20 CN CN028151046A patent/CN1537000B/zh not_active Expired - Fee Related
- 2002-07-20 HU HU0401406A patent/HUP0401406A3/hu unknown
- 2002-07-20 JP JP2003516518A patent/JP4676697B2/ja not_active Expired - Fee Related
- 2002-07-20 RS YU6104A patent/RS6104A/sr unknown
- 2002-07-20 HR HR20040108A patent/HRP20040108A2/hr not_active Application Discontinuation
- 2002-07-20 NZ NZ530887A patent/NZ530887A/en not_active IP Right Cessation
- 2002-07-20 PT PT02764740T patent/PT1414444E/pt unknown
- 2002-07-20 AU AU2002328931A patent/AU2002328931B2/en not_active Ceased
- 2002-07-20 DE DE60226032T patent/DE60226032T2/de not_active Expired - Lifetime
- 2002-07-20 KR KR1020047001524A patent/KR100910930B1/ko not_active Expired - Fee Related
- 2002-07-20 DK DK02764740T patent/DK1414444T3/da active
- 2002-07-20 WO PCT/EP2002/008106 patent/WO2003011288A1/en not_active Ceased
- 2002-07-20 MX MXPA04000041A patent/MXPA04000041A/es active IP Right Grant
- 2002-07-20 ES ES02764740T patent/ES2301673T3/es not_active Expired - Lifetime
- 2002-07-20 RU RU2004105966/04A patent/RU2318815C2/ru not_active IP Right Cessation
- 2002-07-20 AT AT02764740T patent/ATE391504T1/de active
- 2002-07-26 PE PE2002000672A patent/PE20030348A1/es not_active Application Discontinuation
- 2002-07-30 MY MYPI20022873A patent/MY133467A/en unknown
- 2002-07-30 AR ARP020102868A patent/AR036349A1/es active IP Right Grant
- 2002-07-30 TW TW091116941A patent/TWI325863B/zh not_active IP Right Cessation
- 2002-07-31 US US10/208,182 patent/US6962937B2/en not_active Expired - Lifetime
2004
- 2004-01-12 ZA ZA200400194A patent/ZA200400194B/xx unknown
- 2004-01-26 CO CO04005444A patent/CO5550452A2/es not_active Application Discontinuation
- 2004-01-27 IL IL160093A patent/IL160093A/en not_active IP Right Cessation
- 2004-01-30 NO NO20040426A patent/NO326696B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HRP20040108A2 (en)	2004-06-30
TWI325863B (en)	2010-06-11
RU2004105966A (ru)	2005-06-27
US6962937B2 (en)	2005-11-08
MXPA04000041A (es)	2004-05-21
HK1066166A1 (zh)	2005-03-18
RU2318815C2 (ru)	2008-03-10
CO5550452A2 (es)	2005-08-31
BR0211535A (pt)	2004-07-13
WO2003011288A1 (en)	2003-02-13
PL365396A1 (en)	2005-01-10
AR036349A1 (es)	2004-09-01
DE10137595A1 (de)	2003-02-13
NO20040426L (no)	2004-03-26
DE60226032D1 (de)	2008-05-21
HUP0401406A3 (en)	2004-11-29
EP1414444B1 (de)	2008-04-09
US20030109497A1 (en)	2003-06-12
CA2455966A1 (en)	2003-02-13
AU2002328931B2 (en)	2008-04-24
CA2455966C (en)	2011-09-20
NO326696B1 (no)	2009-02-02
PE20030348A1 (es)	2003-05-14
EP1414444A1 (de)	2004-05-06
CN1537000B (zh)	2010-05-12
PT1414444E (pt)	2008-05-27
ZA200400194B (en)	2005-03-14
DE60226032T2 (de)	2009-05-20
DK1414444T3 (da)	2008-08-04
KR20040020076A (ko)	2004-03-06
IL160093A0 (en)	2004-06-20
ES2301673T3 (es)	2008-07-01
JP4676697B2 (ja)	2011-04-27
KR100910930B1 (ko)	2009-08-06
MY133467A (en)	2007-11-30
RS6104A (sr)	2006-10-27
JP2005504033A (ja)	2005-02-10
IL160093A (en)	2009-05-04
CN1537000A (zh)	2004-10-13
NZ530887A (en)	2005-09-30
HUP0401406A2 (hu)	2004-10-28

Legal Events

Date

Code

Title

Description

2008-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1414444

Country of ref document: EP

Publication	Publication Date	Title
DE50312747D1 (de)	2010-07-08	Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
DE60113719D1 (de)	2006-02-09	Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE50209483D1 (de)	2007-03-29	Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ATE425979T1 (de)	2009-04-15	Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel
DE60034683D1 (de)	2007-06-14	3(5)-ureido-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
DE50015711D1 (de)	2009-09-24	In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
DE60107859D1 (de)	2005-01-20	Benzimidazolderivate, ihre herstellung und therapeutische verwendung
ATE323079T1 (de)	2006-04-15	Neue sulfamiden und deren verwendung als endothelin-antagonisten
DE50207522D1 (de)	2006-08-24	Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE50009118D1 (de)	2005-02-03	Heterozyklisch substituierte benzimidazole, deren herstellung und anwendung
DE50111690D1 (de)	2007-02-01	2-acyl-indolderivate und deren verwendung als antitumormittel
DE60130834D1 (de)	2007-11-22	Zusammensetzungen gegen schlechte Gerüche, deren Herstellung und Verwendung
EP1299415A4 (de)	2005-01-19	Modulatoren von chemokinrezeptoren, deren herstellung und verwendung
DE60325493D1 (de)	2009-02-05	Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten
DE60106607D1 (de)	2004-11-25	Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE357448T1 (de)	2007-04-15	Benzoxazinonderivative, deren herstellung und verwendung
ATE312828T1 (de)	2005-12-15	Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
ATE242197T1 (de)	2003-06-15	3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
DE50113867D1 (de)	2008-05-29	Neue indolderivate und deren verwendung als arzneimittel
DE60005690D1 (de)	2003-11-06	Titanverbindungen, deren herstellung und verwendung
DE50206476D1 (de)	2006-05-24	Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
DE602004015600D1 (de)	2008-09-18	Neue imidazolderivative, deren herstellung und deren verwendung als medikament
ATE329908T1 (de)	2006-07-15	Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
ATE362490T1 (de)	2007-06-15	Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
DE60126614D1 (de)	2007-03-29	1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten